Pfizer Inc. (NYSE:PFE) Shares Acquired by Evergreen Capital Management LLC

Evergreen Capital Management LLC raised its position in Pfizer Inc. (NYSE:PFE - Free Report) by 50.6% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 486,702 shares of the biopharmaceutical company's stock after purchasing an additional 163,439 shares during the period. Evergreen Capital Management LLC's holdings in Pfizer were worth $12,912,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in PFE. Retirement Wealth Solutions LLC acquired a new position in Pfizer during the fourth quarter worth $26,000. Rialto Wealth Management LLC purchased a new position in shares of Pfizer during the 4th quarter worth $26,000. Kohmann Bosshard Financial Services LLC acquired a new position in shares of Pfizer during the 4th quarter valued at about $28,000. Noble Wealth Management PBC purchased a new stake in shares of Pfizer in the fourth quarter valued at about $31,000. Finally, Curio Wealth LLC acquired a new stake in Pfizer during the fourth quarter worth about $32,000. Institutional investors and hedge funds own 68.36% of the company's stock.

Insiders Place Their Bets

In related news, Director Ronald E. Blaylock acquired 19,457 shares of the stock in a transaction dated Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, with a total value of $499,072.05. Following the completion of the transaction, the director now owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. 0.06% of the stock is owned by company insiders.

Pfizer Stock Up 0.4 %

Shares of NYSE PFE traded up $0.09 during midday trading on Friday, hitting $22.13. The company's stock had a trading volume of 53,854,504 shares, compared to its average volume of 40,486,092. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The firm has a market capitalization of $125.50 billion, a price-to-earnings ratio of 15.69, a price-to-earnings-growth ratio of 0.64 and a beta of 0.67. The business's fifty day simple moving average is $24.88 and its two-hundred day simple moving average is $26.15. Pfizer Inc. has a 1 year low of $20.92 and a 1 year high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating the consensus estimate of $0.48 by $0.15. The company had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm's revenue was up 24.7% compared to the same quarter last year. During the same quarter last year, the company posted $0.10 EPS. On average, equities analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.

Analysts Set New Price Targets

Several analysts have recently weighed in on the stock. UBS Group dropped their price target on shares of Pfizer from $28.00 to $24.00 and set a "neutral" rating for the company in a research note on Tuesday, April 8th. Guggenheim reiterated a "buy" rating on shares of Pfizer in a research report on Tuesday, March 18th. Citigroup restated a "neutral" rating on shares of Pfizer in a research report on Thursday, March 27th. Hsbc Global Res upgraded Pfizer to a "strong-buy" rating in a report on Monday, March 10th. Finally, The Goldman Sachs Group restated a "neutral" rating and issued a $25.00 price objective (down from $32.00) on shares of Pfizer in a report on Tuesday, April 8th. One research analyst has rated the stock with a sell rating, eight have issued a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company's stock. According to data from MarketBeat, Pfizer has an average rating of "Moderate Buy" and a consensus price target of $31.07.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.